BioNTech Results Presentation Deck

Capital Allocation Framework 31 R&D Activities Accelerate R&D activities in the years to come Corporate and Infrastructure Develop global footprint and invest in manufacturing capabilities for key technologies 1 Based on the shares outstanding as of March 30, 2022 and pending approval at the AGM to be held in June 2022. M&A and Business Development Strengthen technology platforms and digital capabilities by collaborations and potential add-on M&A Return Capital to Shareholders Expect to authorize a share repurchase program of up to $1.5 bn over the next two years. Will propose a special cash dividend of €2.00 per share, aggregate of ~€0.5 bn¹ BIONTECH

View entire presentation